Find, compare & contact
Ibandronate
API Manufacturers & Suppliers
Pakistan
Filters
Reset current filters
Type
Production region
Qualifications
Country of origin
Follow us
Producer
Produced in:
Established in: 1951
MOQ: -
Employees: 455+
Largest Polish manufacturer of pharmaceuticals and a leader of the Polish pharmaceutical market.
FDA approved european manufcaturing facilities
Export APIs to more than 60 countries worldwide
+ 0
All certificates
Producer
Produced in:
Established in: 2021
MOQ: -
Employees: 19
API, Intermediates, Building Blocks, Impurities, Amino acids and Peptides
Small quantity APIs to commercial scale
GMP and USFDA certification based on quantity, order, assignment.
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
Producer
Produced in:
Established in: 1984
MOQ: -
Employees: 21,650
Diverse portfolio of 180+APIs
1754+ DMF across global markets
1100+ patents filed, and more than 70 own patents granted
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
How does it work?
You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry
Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only
Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week
Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news
Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module
Looking for Ibandronate API 114084-78-5?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Ibandronate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Ibandronate
- Synonyms:
- Bondronat , Ibandronic Acid , Ibandronate Sodium Monohydrate
- Cas Number:
- 114084-78-5
- DrugBank number:
- DB00710
- Unique Ingredient Identifier:
- UMD7G2653W
About Ibandronate
Do you want to know more about Ibandronate? You can find a small explanation about it here. Ibandronate, or BM0955, is a third generation, nitrogen containing bisphosphonate similar to zoledronic acid, minodronic acid, and risedronic acid It is used to prevent and treat postmenopausal osteoporosis Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs. Ibandronate was granted FDA approval on 16 May 2003.
Check who is selling Ibandronate in the overview above.
Ibandronate is a type of Bisphosphonates
Bisphosphonates are a vital subcategory of pharmaceutical active pharmaceutical ingredients (APIs) widely used in the treatment of various bone-related conditions. These compounds play a crucial role in inhibiting bone resorption, making them particularly effective in managing diseases such as osteoporosis, Paget's disease, and bone metastasis associated with cancer.
The mechanism of action of bisphosphonates involves their binding to hydroxyapatite crystals in bone, leading to the suppression of osteoclast activity. By inhibiting the breakdown of bone tissue, these APIs help to maintain bone density and strength, thereby reducing the risk of fractures and improving overall bone health.
One of the key advantages of bisphosphonates is their high affinity for bone tissue, which allows for targeted treatment. They are administered orally or intravenously, depending on the specific formulation and indication. Commonly prescribed bisphosphonates include alendronate, ibandronate, and zoledronic acid, among others.
Bisphosphonates are generally well-tolerated, although some potential side effects, such as gastrointestinal disturbances or musculoskeletal pain, may occur. These APIs are metabolized in the liver and excreted through the kidneys.
Due to their effectiveness and widespread clinical use, bisphosphonates have gained significant attention in the pharmaceutical industry. Continuous research and development efforts are focused on improving their therapeutic profiles, including enhancing potency and reducing side effects.
In summary, bisphosphonates are a critical subcategory of pharmaceutical APIs employed in the management of bone-related disorders. Their targeted action on bone tissue and ability to inhibit bone resorption make them indispensable in the treatment of conditions like osteoporosis and bone metastasis. Ongoing advancements in this field are expected to further optimize their therapeutic benefits in the future.
Ibandronate (Bisphosphonates), classified under Metabolic Bone Disease Agents
Metabolic Bone Disease Agents are a category of pharmaceutical active pharmaceutical ingredients (APIs) that are specifically designed to treat and manage conditions related to the bones and their metabolism. These agents play a crucial role in the treatment of various metabolic bone diseases, including osteoporosis, Paget's disease, and rickets.
The primary function of Metabolic Bone Disease Agents is to regulate bone remodeling and maintain bone health. They achieve this by targeting specific pathways involved in bone metabolism, such as osteoclast and osteoblast activity, calcium regulation, and vitamin D metabolism.
These APIs are commonly used in the development of medications, including oral tablets, injectables, and topical formulations, for the effective treatment of metabolic bone diseases. They are carefully formulated to optimize their pharmacokinetic and pharmacodynamic properties, ensuring maximum efficacy and minimal side effects.
Metabolic Bone Disease Agents encompass a range of substances, including bisphosphonates, selective estrogen receptor modulators (SERMs), calcitonin, and vitamin D analogs. These APIs act through different mechanisms to address specific aspects of bone health, such as inhibiting bone resorption, promoting bone formation, or regulating calcium levels.
In conclusion, Metabolic Bone Disease Agents are a vital category of pharmaceutical APIs used in the development of medications for the treatment and management of various metabolic bone diseases. These agents target specific pathways involved in bone metabolism to regulate bone remodeling, enhance bone health, and alleviate the symptoms associated with these conditions.
Ibandronate manufacturers | traders | suppliers
We have 7 companies offering Ibandronate produced in 2 different countries.
Get in contact with the supplier of your choice:
- Polpharma from Poland, product country of origin Poland
- SETV Global from India, product country of origin India
- Natco Pharma from India, product country of origin India
- JPN Pharma from India, product country of origin India
- Dr. Reddy's from India, product country of origin India
- Emcure Pharma from India, product country of origin India
- Sun Pharma from India, product country of origin India
Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.
You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.
